Marieke Fransen

11PUBLICATIONS
60CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsTumour immunologyMedical devicesGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 22, 2026
Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial.

|Nov 28, 2025
Immune-modulating effects on tumor-draining lymph nodes of neoadjuvant chemoradiotherapy combined with dual immunotherapy in patients with T3-4N0-2 NSCLC.

Ezgi B Ulas, Sofie J I Koomen, Anne Vrijmoet

|Dec 17, 2024
Evaluation of Spliceosome Protein SmD2 as a Potential Target for Cancer Therapy.

Jing Li, Peiyu Li, Tereza Brachtlova

|Sep 30, 2024
Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study.

Idris Bahce, Chris Dickhoff, Famke L Schneiders

|Jun 27, 2023
A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell-Mediated Immune Response against EGFR-Expressing Tumors.

Lisa A King, Elisa C Toffoli, Myrthe Veth

|Jul 20, 2022
Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic T<sub>reg</sub> reduction and effector T cell activation.

Kim M van Pul, Jessica C L Notohardjo, Marieke F Fransen

Pageof 2

Frequent Collaborators

3 joint publications

Febe van Maldegem

3 joint publications

Ezgi B Ulas

3 joint publications

Suresh Senan

3 joint publications

Idris Bahce